On the other hand, despite ameliorating hepatic steatosis and fibrosis, the farnesoid X receptor (FXR) agonist obeticholic acid was found to increase a) insulin resistance, estimated by HOMA‐IR and b) circulating levels of low‐density lipoproteins, resulting in a more proatherogenic profile.131. This evidence concerns the gene NR1H4 and Hepatic steatosis.